A compound of Formula or a stereoisomer or tautomeric form thereof, wherein: Each X independently represents CR 7; R a, R b and R c are independently selected from the group consisting of Hydrogen, Fluoro, Bromo, Chloro, -CHF 2, -CF 2 -methyl, -CH 2 F, -CF 3, -OCF 3, -CN, C 1 -C 3 alkyl and C 3 -C 4 cycloalkyl; R 4 is Hydrogen, C 1 -C 3 alkyl or C 3 -C 4 cycloalkyl; R 5 is Hydrogen; R 6 is selected from the group consisting of C 2 -C 6 alkyl, C 1 -C 4 alkyl-R 8 optionally substituted with one or more Fluoro, C 1 -C 4 alkyl-R 9 optionally substituted with one or more Fluoro, and a 3-7 membered mono- or polycyclic saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring or C 2 -C 6 alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of Hydrogen, -OH, Fluoro, oxo, R 9, R 10 and C 1 -C 4 alkyl optionally substituted with R 10; R 7 represents hydrogen, -CN, Fluoro, Chloro, Bromo, -CHF 2, -CF 2 -methyl, -CH 2 F,-CF 3, C 1 -C 3 alkyl or C 3 -C 4 cycloalkyl; R 8 represents 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more C 1 -C 4 alkyl optionally substituted with R 10; R 9 represents, C 1 -C 4 alkyloxy, -SO 2 -methyl, -C(=O)-OR 11 or -C(=O)-N(R 11) 2; R 10 represents -CN, -OH, Fluoro, -CHF 2, -CH 2 F or -CF 3; R 11 represents hydrogen or C 1 -C 3 alkyl; or a pharmaceutically acceptable salt or a solvate thereof wherein such compound is not Each X independently represents CR 7; R a, R b and R c are independently selected from the group consisting of Hydrogen, Fluoro, Bromo, Chloro, -CHF 2, -CF 2 -methyl, -CH 2 F, -CF 3, -OCF 3, -CN, C 1 -C 3 alkyl and C 3 -C 4 cycloalkyl; R 4 is Hydrogen, C 1 -C 3 alkyl or C 3 -C 4 cycloalkyl; R 5 is Hydrogen; R 6 is selected from the group consisting of C 2 -C 6 alkyl, C 1 -C 4 alkyl-R 8 optionally substituted with one or more Fluoro, C 1 -C 4 alkyl-R 9 optionally substituted with one or more Fluoro, and a 3-7 membered mono- or polycyclic saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring or C 2 -C 6 alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of Hydrogen, -OH, Fluoro, oxo, R 9, R 10 and C 1 -C 4 alkyl optionally substituted with R 10; R 7 represents hydrogen, -CN, Fluoro, Chloro, Bromo, -CHF 2, -CF 2 -methyl, -CH 2 F,-CF 3, C 1 -C 3 alkyl or C 3 -C 4 cycloalkyl; R 8 represents 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more C 1 -C 4 alkyl optionally substituted with R 10; R 9 represents, C 1 -C 4 alkyloxy, -SO 2 -methyl, -C(=O)-OR 11 or -C(=O)-N(R 11) 2; R 10 represents -CN, -OH, Fluoro, -CHF 2, -CH 2 F or -CF 3; R 11 represents hydrogen or C 1 -C 3 alkyl; or a pharmaceutically acceptable salt or a solvate thereof wherein such compound is not